A Comparative Study of Scientific Publications in Health Care Sciences and Services from Mainland China, Taiwan, Japan, and India (2007–2014)

Lv, Yipeng; Tang, Bihan; Xu, Liu; Xue, Chen; Liu, Yuan; Peng, Kang-Lin; Zhang, Lulu

doi:10.3390/ijerph13010079

“…Both vehicles may induce mast cell/basophil activation and subsequent hypersensitivity reaction. Other drugs that are formulated in Cremophor EL (cyclosporine, teniposide, ixabepilone) or polysorbate 80 (etoposide) may trigger similar reactions and should be avoided in patients with a history of IRs following taxane administration [56,57]. Histamine receptor antagonists and steroids are recommended as standard prophylaxis prior to taxane administration, which has reduced the incidence of taxane-induced bronchospasm from 30% to 2% [58].…”

Section: Specific Clinical and Histopathologicmentioning

confidence: 99%

Cancer Treatment-Related Lung Injury

Shannon

¹

2019

Oncologic Critical Care

View full text Add to dashboard Cite

Lung injury associated with cancer therapeutics is often the limiting factor that trumps otherwise successful cancer therapy. Thoracic radiation as well as cancer pharmacotherapeutics, including conventional chemotherapy, molecular targeted agents, and cancer immunotherapies, have been associated with a unique spectrum of histopathologic injury patterns that may involve the lung parenchyma, pleura, airways, and/or pulmonary vasculature. Injury patterns may be idiosyncratic, unpredictable, and highly variable from one agent class to the next. Variability in lung injury patterns within a specific therapeutic class of drugs also occurs, adding to the conundrum. Drug-induced toxicities to the thoracic cavity are infrequent, and early recognition of clinical clues portends a good outcome in most cases. Failure to recognize early clinical signs, however, may result in irreversible and potentially lethal consequences. This chapter provides an overview of our current knowledge of thoracic complications associated with cancer pharmacotherapies.

show abstract

“…Both vehicles may induce mast cell/basophil activation and subsequent hypersensitivity reaction. Other drugs that are formulated in Cremophor EL (cyclosporine, teniposide, ixabepilone) or polysorbate 80 (etoposide) may trigger similar reactions and should be avoided in patients with a history of IRs following taxane administration [56,57]. Histamine receptor antagonists and steroids are recommended as standard prophylaxis prior to taxane administration, which has reduced the incidence of taxaneinduced bronchospasm from 30% to 2% [58].…”

Section: Specific Clinical and Histopathologicmentioning

confidence: 99%